Dr. Duaa Jabari, MD

Dr. Jabari practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Jabari's NPI, 1124374442, was assigned on July 24, 2012. Dr. Jabari graduated from University of Tichreen Faculty of Medicine in 2004. Dr. Jabari holds California license C183670.

Dr. Jabari's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Jabari's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jabari practices. Vendor and product names are available with a free account.

Neurology is Dr. Jabari's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Jabari is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Jabari's licenses on file in 5 states: California, Mississippi, Texas, Missouri and Kansas.

Dmand AI lists encephalopathy, hereditary polyneuropathy, lower back pain, muscle disease, muscle pain, fibromyalgia, and limb pain, nerve damage and neuropathy among the conditions Dr. Jabari treats.

CMS data shows 432 Medicare services from Dr. Jabari across 10 procedure codes in 2024, for 237 Medicare patients. Medicare paid $38,670 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 237 Medicare patients who saw Dr. Jabari in 2024. The largest group is 65 to 74, with 95 patients. 75% of them have high cholesterol, and 72% have arthritis. 26% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jabari's median patient age at 68, with 49% women.

In 2024, Dr. Jabari wrote 214 Medicare Part D claims for 39 patients. 48% of them were for generic drugs. CMS names the drug for 150 of them, across 5 drugs with 11 or more claims each, at $624,386 in total drug cost. In 2023, CMS named 573 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Jabari for performance year 2024, reported as part of a group. Dr. Jabari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jabari as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Jabari in 2014.

Dmand AI links Dr. Jabari to 5 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Amyotrophic Lateral Sclerosis, TDP-43 Proteinopathies and Distal myopathy, Nonaka type. ZevraDenmark sponsors the most, 2.

CMS Open Payments shows 31 general payments to Dr. Jabari from 7 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 73% of the total. Sarepta Therapeutics, Inc. paid the most, $8,222.

Dr. Jabari graduated from University of Tichreen Faculty of Medicine in 2004.

Dr. Jabari is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.